Similar articles

• Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

  Peters DH, Benfield P. Peters DH, et al. Pharmacoeconomics. 1994 Oct;6(4):370-400. doi: 10.2165/00019053-199406040-00004. Pharmacoeconomics. 1994. PMID: 10147474 Review.
• Health and cost benefits associated with the use of metoprolol in heart attack patients.

  Fernández-Jiménez R, Ibanez B. Fernández-Jiménez R, et al. Expert Rev Clin Pharmacol. 2014 Nov;7(6):687-9. doi: 10.1586/17512433.2014.960847. Epub 2014 Sep 18. Expert Rev Clin Pharmacol. 2014. PMID: 25231274
• Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol.

  Olsson G, Levin LA, Rehnqvist N. Olsson G, et al. Br Med J (Clin Res Ed). 1987 Feb 7;294(6568):339-42. doi: 10.1136/bmj.294.6568.339. Br Med J (Clin Res Ed). 1987. PMID: 3101865 Free PMC article. Clinical Trial.
• [MIAMI study--the advantage of acute treatment with metoprolol in AMI (suspected and clear). Metoprolol In Acute Myocardial Infarction].

  Hjalmarson A. Hjalmarson A. Cardiologia. 1984 Jan-Feb;29(1-2):145-56. Cardiologia. 1984. PMID: 6398705 Clinical Trial. Italian. No abstract available.
• [Reduction of cholesterol and myocardial infarction. Big differences between different groups when it comes to the therapeutic effect].

  Håkansson J. Håkansson J. Lakartidningen. 1997 Dec 3;94(49):4619, 4622-3. Lakartidningen. 1997. PMID: 9445934 Review. Swedish. No abstract available.